Clinical trial
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple…
NCT00099502 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00099502 |
|---|---|
| Title | BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients |
| Official title | International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone |
| Enrollment | 2,244 |
| Start date | Nov 1, 2003 |
| Completion | Aug 1, 2007 |
| First posted | Dec 16, 2004 |
| Last update posted | Dec 19, 2008 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary and 14 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: